Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

20 of 25 arms with a reported figure. Choose arms to narrow the chart.

months 10

Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source). median progression-free survival: 7.8 months, ASCO 2026; post hoc

Lenvatinib (off Label) 24 mg. median progression-free survival: 17.5 months, 8 progression events

Lenvatinib (off Label) 24 mg. median progression-free survival: 9.1 months, primary analysis

Axitinib (off Label) 5 mg. median progression-free survival: 10.8 months, primary analysis

Axitinib (off Label) none. median progression-free survival: 2.8 months, primary analysis

Axitinib (off Label) axitinib 5 mg twice daily + avelumab. median progression-free survival: 7.3 months, primary analysis

Axitinib (off Label) as above. median progression-free survival: 1.8 months, updated analysis; exploratory

Axitinib (off Label) as above. median progression-free survival: 11.4 months, updated analysis; HR 0.14 vs ACC-I

Rivoceranib 700 mg. median progression-free survival: 9 months, primary analysis

Amivantamab not stated in source. median progression-free survival: 4.6 months, results posted 05.08.2026

Bars in this group share the unit months. 17.5 months is the longest reported value here. A different unit is not redrawn onto this scale.

% 2

Axitinib (off Label) 5 mg. 6-month progression-free survival: 73%, 6 months

Axitinib (off Label) none. 6-month progression-free survival: 23%, 6 months

Bars in this group share the unit %. 73 % is the longest reported value here. A different unit is not redrawn onto this scale.

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.